NA
ZNTL icon

NewEdge Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

NewEdge Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10
Closed -$201 – 4198
2022
Q4 		$201 Buy
+10
New +$215 ﹤0.01% 3302

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NewEdge Advisors's ZNTL Position: Q1 2023 in Review

NewEdge Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2023, closing a stake of 10 shares — an estimated $201 sold.

NewEdge Advisors first reported a position in ZNTL in Q4 2022 and held it in 1 quarter. The position peaked at $201 in Q4 2022. 110 funds tracked by Wall St. Rank hold ZNTL as of Q1 2023.

  • NewEdge Advisors reported no remaining Zentalis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • NewEdge Advisors sold 10 Zentalis Pharmaceuticals shares in Q1 2023, an estimated $201.
  • NewEdge Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • NewEdge Advisors's Zentalis Pharmaceuticals position peaked at $201 in Q4 2022.
  • 110 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.